These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33121320)

  • 1. Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases.
    Xuan L; Sun B; Meng X; Liu C; Cong Y; Wu S
    Cancer Biol Ther; 2020 Nov; 21(11):990-993. PubMed ID: 33121320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel-induced acute myositis: a case report with review of literature.
    Wongsaengsak S; Quirch M; Ball S; Sultan A; Jahan N; Elmassry M; Rehman S
    J Chemother; 2021 Apr; 33(2):116-121. PubMed ID: 32619151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.
    Xie H; Liu J; Yu S; Chen Y; Zheng M; Deng Y; Wang S; Jiang J; Li Y; Li H; Kang H; Zhang C; Zhang GJ; Su F; Cheng A; Wang S
    Adv Ther; 2019 Jan; 36(1):131-146. PubMed ID: 30511279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
    van Dooijeweert C; van der Wall E; Baas IO
    Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
    Antolín-Novoa S; Blanco-Campanario E; Antón A; Gallegos-Sancho MI; Pérez-Carrión R; Peláez I; Galán-Brotons A; de la Cruz-Merino L; Murías-Rosales A;
    Clin Transl Oncol; 2015 Nov; 17(11):862-9. PubMed ID: 26103952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
    Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
    BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
    Layman RM; Thomas DG; Griffith KA; Smerage JB; Helvie MA; Roubidoux MA; Diehl KM; Newman LA; Sabel MS; Hayman JA; Pierce LJ; Hayes DF; Schott AF
    Clin Cancer Res; 2007 Jul; 13(14):4092-7. PubMed ID: 17634534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy for Operable Breast Cancer Patients (N-1 Study).
    Nakagawa M; Ikeuchi M; Morimoto M; Takechi H; Toba H; Yoshida T; Okumura K; Hino N; Nishisho A; Tangoku A
    Clin Breast Cancer; 2019 Feb; 19(1):10-16. PubMed ID: 30340871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].
    Lopez M; Di Lauro L; Viola G; Conti F; Foggi P; Vici P
    Clin Ter; 2009; 160(6):489-97. PubMed ID: 20198293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer.
    Yardley DA; Shipley D; Zubkus J; Wright GL; Ward PJ; Mani A; Shastry M; Finney L; DeBusk L; Hainsworth JD
    Clin Breast Cancer; 2019 Feb; 19(1):1-9. PubMed ID: 30245148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences.
    Hellerstedt-Börjesson S; Nordin K; Fjällskog ML; Rissanen R; Peterson M; Arving C
    Scand J Pain; 2018 Oct; 18(4):581-591. PubMed ID: 29949517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer].
    Wu SK; Ma Y; Meng XY; Sun B; Wang T; Zhang SH; Jiang ZF; Song ST
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):764-9. PubMed ID: 23291071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: a randomized clinical study.
    Dhanraj KM; Dubashi B; Gollapalli S; Kayal S; Cyriac SL
    Med Oncol; 2015 Dec; 32(12):261. PubMed ID: 26520144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare case of isolated adrenal metastasis of invasive ductal breast carcinoma.
    Andjelić-Dekić N; Božović-Spasojević I; Milošević S; Matijašević M; Karadžić K
    Srp Arh Celok Lek; 2014; 142(9-10):597-601. PubMed ID: 25518541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
    Priyadarshini R; Raj GM; Kayal S; Ramesh A; Shewade DG
    J Clin Pharm Ther; 2019 Apr; 44(2):188-196. PubMed ID: 30637776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.